AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04951791
Drug: SMOFlipid
RxNorm normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
Trial: NCT05292417
Drug: sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
Trial: NCT05292417
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
Trial: NCT05292417
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
Trial: NCT00034619
Drug: ALIMTA
RxNorm normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00034619
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05015621
Drug: Surufatinib plus Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Trial: NCT04926259
Drug: 18F-T807
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
Trial: NCT01491139
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given twice daily. Exposure will escalate by daily dose and duration.
Trial: NCT01491139
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose will be 35mg/m2 i.v. once weekly.
Trial: NCT05703984
Drug: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
RxNorm normalized name: metformin and linagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Trial: NCT05703984
Drug: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
RxNorm normalized name: metformin and linagliptin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Trial: NCT05513729
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
Trial: NCT05513729
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
Trial: NCT05200286
Drug: Olorofim
RxNorm normalized name: Olorofim
DrugBank: Olorofim (DB15245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT04728035
Drug: Irinotecan Liposome Injection
RxNorm normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan Liposome Injection
Trial: NCT04876430
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
Trial: NCT06619301
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
Trial: NCT03923556
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
Trial: NCT03923556
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
Trial: NCT06413056
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
Trial: NCT06413056
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
Trial: NCT05725252
Drug: NVP-2203
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)
Trial: NCT05936606
Drug: Clopidogrel monotherapy
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.
Trial: NCT06303076
Drug: Tizanidine Hcl 4Mg Tab
RxNorm normalized name: TIZANIDINE HCL 4MG TAB
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial Dose Administration:~Patients will start by taking an initial dose of 2 mg of Tizanidine at bedtime (HS).~Dose Titration Process:~Every 4 days, the dose of Tizanidine will be increased by 2 mg. This titration is based on the patient's response to the medication and their tolerability of it.~Maximum Dose Limit:~The dose titration will continue until reaching the maximum dose of 0.1 mg/kg/HS, or until the maximum tolerated dose is identified, whichever comes first.~Monitoring and Adjustment:~Throughout the titration process, patients will be closely monitored for any adverse effects and for the effectiveness of the medication.~Adjustments to the dosing schedule may be made based on the clinician's assessment of tolerability and therapeutic response.
Trial: NCT00000178
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06303076
Drug: Zolpidem Tartrate 10 mg
RxNorm normalized name: zolpidem tartrate 10 MG
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nitial Dose Administration:~Participants will start by taking an initial dose of Zolpidem 5 mg orally at home before bedtime (HS).~Response Evaluation and Dose Adjustment:~If there is no response to the initial 5 mg dose and it is tolerated well by the participant, the dose will be increased to 10 mg.~Monitoring and Adjustment:~Participants will be monitored for their response to the medication as well as for any adverse effects.~The decision to increase the dose to 10 mg will be based on the absence of a therapeutic response to the initial dose and the participant's tolerability of Zolpidem.~Dose Maximization and Safety:~The increase to a 10 mg dose is aimed at maximizing therapeutic efficacy while ensuring the safety and tolerability of the medication in participants who do not respond to the lower dose.
Trial: NCT00035035
Drug: GEMZAR
RxNorm normalized name: Gemzar
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00035035
Drug: ALIMTA
RxNorm normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05276232
Drug: Cannabis(THC) inhaled
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis vapor is produced from 500mg, approximately 5-10% High dose bulk cannabis plant material, 30-37.5 mg THC
Trial: NCT02094222
Drug: RAVICTI
RxNorm normalized name: Ravicti
DrugBank: Glycerol phenylbutyrate (DB08909)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
Trial: NCT04473820
Drug: Lidocaine-Prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
Trial: NCT00001998
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05636787
Drug: Treosulfan
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
Trial: NCT05636787
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
Trial: NCT05709353
Drug: MDMA
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
Trial: NCT05709353
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
Trial: NCT04704154
Drug: Regorafenib, (Stivarga, BAY73-4506)
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intake orally, starting with 3x 30 mg tablets every day (once daily.) for 21 days of every 28-day cycle (21 days on, 7 days off).~If the starting dose is well tolerated dose can be escalated to 120 mg (4x30 mg tablets).
Trial: NCT04704154
Drug: Nivolumab (Opdivo)
RxNorm normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg administered on Day 1 of each treatment cycle.
Trial: NCT05252845
Drug: PQ
RxNorm normalized name: PQP
DrugBank: p-Quaterphenyl (DB12794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
Trial: NCT05176626
Drug: Phentermine Hydrochloride 8 MG
RxNorm normalized name: phentermine hydrochloride 8 MG
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
Trial: NCT04766996
Drug: Baby aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baby aspirin 81mg: Twice daily for 6 weeks after surgery
Trial: NCT04766996
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery
Trial: NCT04766996
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 5mg: Daily for three weeks after surgery
Trial: NCT04766996
Drug: Prilosec
RxNorm normalized name: Prilosec
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery
Trial: NCT04766996
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
Trial: NCT04766996
Drug: Voltaren
RxNorm normalized name: Voltaren
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
Trial: NCT04766996
Drug: Zofran
RxNorm normalized name: Zofran
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zofran 4 mg pre-operative
Trial: NCT04766996
Drug: Pepcid
RxNorm normalized name: Pepcid
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pepcid 20 mg pre-operative
Trial: NCT04766996
Drug: Reglan
RxNorm normalized name: Reglan
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reglan 10 mg pre-operative
Trial: NCT04766996
Drug: Versed
RxNorm normalized name: Versed
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Versed 2 mg pre-operative
Trial: NCT04766996
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
Trial: NCT04766996
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 10-125 mcg/kg/min intraoperative
Trial: NCT04766996
Drug: Ancef
RxNorm normalized name: Ancef
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ancef 2-3 gm weight-based dosing intraoperative
Trial: NCT04766996
Drug: Tranexamic Acid (TXA)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) 2 gm intraoperative
Trial: NCT04766996
Drug: Decadron
RxNorm normalized name: Decadron
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Decadron 10 mg intraoperative
Trial: NCT04766996
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
Trial: NCT04766996
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
Trial: NCT05220462
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As per Remimazolam arm
Trial: NCT05220462
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As per Midazolam arm
Trial: NCT06320431
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrombolytic
Trial: NCT04905277
Drug: Atenolol 50 MG
RxNorm normalized name: atenolol 50 MG
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg Atenolol daily
Trial: NCT05982301
Drug: Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
Trial: NCT04543188
Drug: PF-07284890
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Trial: NCT04543188
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Trial: NCT04543188
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
Trial: NCT04378959
Drug: Lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Trial: NCT06356974
Drug: Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
Trial: NCT04504825
Drug: CAEL-101
RxNorm normalized name: Immunoglobulin g1, anti-(human amyloid fibril) (human-mus musculus monoclonal cael-101 .gamma.1-chain), disulfide with human-mus musculus monoclonal cael-101 .kappa.-chain, dimer
DrugBank: Anselamimab (DB17492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
Trial: NCT05806567
Drug: Belumosudil
RxNorm normalized name: BELUMOSUDIL
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT03615547
Drug: Clomifene Citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day.
Trial: NCT06619145
Drug: Low dose Oliceridine
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose Oliceridine
Trial: NCT06619145
Drug: High dose Oliceridine
RxNorm normalized name: Oliceridine
DrugBank: Oliceridine (DB14881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose Oliceridine
Trial: NCT06617182
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
Trial: NCT06617182
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
Trial: NCT06617182
Drug: Thalidomide+Glutamine
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.
Trial: NCT04736927
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 1 and Day 7 as liquid formulation, orally in fed state.